Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency.
暂无分享,去创建一个
[1] J. Bernstein,et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.
[2] J. Bernstein,et al. Facilitating home-based treatment of hereditary angioedema. , 2015, Allergy and asthma proceedings.
[3] H. Longhurst,et al. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk , 2015, Allergy.
[4] T. Craig,et al. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) , 2015, Expert review of clinical immunology.
[5] J. Bernstein,et al. Clinical features of pediatric hereditary angioedema. , 2014, The journal of allergy and clinical immunology. In practice.
[6] H. Farkas,et al. Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] C. Hack,et al. Hereditary Angioedema Attacks: Local Swelling at Multiple Sites , 2016, Clinical Reviews in Allergy & Immunology.
[8] P. Keith,et al. Canadian hereditary angioedema guideline , 2014, Allergy, Asthma & Clinical Immunology.
[9] M. Morfini,et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. , 2014, Blood transfusion = Trasfusione del sangue.
[10] W. Lumry,et al. Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial , 2014, Clinical and experimental immunology.
[11] M. López-Trascasa,et al. Expression of the SERPING1 gene is not regulated by promoter hypermethylation in peripheral blood mononuclear cells from patients with hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.
[12] T. Machnig,et al. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema , 2014, Transfusion.
[13] J. Bernstein,et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[14] K. Beusterien,et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. , 2014, Allergy and asthma proceedings.
[15] T. Horiuchi. [Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research: points for diagnosis and treatment]. , 2014, Arerugi = [Allergy].
[16] C. Hack,et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.
[17] P. Schmid‐Grendelmeier,et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study , 2013, Allergy.
[18] M. Riedl. Hereditary angioedema with normal C1-INH (HAE type III). , 2013, The journal of allergy and clinical immunology. In practice.
[19] J. Bernstein,et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. , 2013, The journal of allergy and clinical immunology. In practice.
[20] M. Maurer,et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe , 2013, Allergy, Asthma & Clinical Immunology.
[21] T. Klingebiel,et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history , 2013, Allergy.
[22] J Dempster,et al. In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency , 2013, Clinical and experimental immunology.
[23] J. Sheikh,et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. , 2013, The Journal of allergy and clinical immunology.
[24] C. Kessler,et al. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates , 2013, Transfusion.
[25] S. D. Del Giacco,et al. Identification of a novel and recurrent mutation in the SERPING1 gene in patients with hereditary angioedema. , 2013, Clinical immunology.
[26] T. Craig,et al. Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration , 2013, International Archives of Allergy and Immunology.
[27] R. Lockey,et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[28] R. Ree,et al. Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies , 2013, Clinical Drug Investigation.
[29] P. Korošec,et al. Hereditary Angioedema Nationwide Study in Slovenia Reveals Four Novel Mutations in SERPING1 Gene , 2013, PloS one.
[30] K. Obtulowicz,et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study , 2013, Allergy.
[31] M. Mannesse,et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. , 2012, Journal of biotechnology.
[32] G. Plosker. Recombinant Human C 1 Inhibitor ( Conestat Alfa ) In the Treatment of Angioedema Attacks in Hereditary Angioedema , 2012 .
[33] M. Mannesse,et al. Immunogenicity Assessment of Recombinant Human C1-Inhibitor , 2012, BioDrugs.
[34] M. Cicardi,et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. , 2012, Allergy and asthma proceedings.
[35] M. Bottorff,et al. Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database , 2012, Pharmacotherapy.
[36] G. Plosker. Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. , 2012, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[37] M. Mannesse,et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. , 2012, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[38] S. Bates. D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders , 2012, Seminars in Thrombosis & Hemostasis.
[39] A. Knulst,et al. Clinical impact of peripheral attacks in hereditary angioedema patients. , 2012, The American journal of medicine.
[40] B. Zuraw,et al. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.
[41] W. Aberer. Hereditary angioedema treatment options: The availability of new therapies , 2012, Annals of medicine.
[42] K. Bork,et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.
[43] T. Machnig,et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. , 2012, Allergy and asthma proceedings.
[44] M. Triggiani,et al. Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[45] J. Bernstein,et al. Progress in the Emergency Management of Hereditary Angioedema: Focus on New Treatment Options in the United States , 2012, Postgraduate medicine.
[46] W. Lumry,et al. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations. , 2012, Allergy and asthma proceedings.
[47] Jay L. Martello,et al. Ecallantide for treatment of acute attacks of hereditary angioedema. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[48] M. Riedl. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. , 2012, Clinical therapeutics.
[49] S. Kivity,et al. Efficacy of Recombinant Human C1 Inhibitor Treatment for Abdominal Attacks of Hereditary Angioedema , 2012 .
[50] Tom Bowen,et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.
[51] M. Triggiani,et al. Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.
[52] M. Cicardi,et al. Target levels of functional C1‐inhibitor in hereditary angioedema , 2012, Allergy.
[53] Tetsurou Yamamoto,et al. Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research - secondary publication. , 2012, Allergology international : official journal of the Japanese Society of Allergology.
[54] T. Machnig,et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.
[55] C. Town,et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[56] B. Chipps. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2011, Pediatrics.
[57] B. Nathanson,et al. Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007. , 2011, Allergy and asthma proceedings.
[58] A. Sheffer,et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. , 2011, The Journal of allergy and clinical immunology.
[59] J. Bernstein,et al. Conestat alfa for the treatment of angioedema attacks , 2011, Therapeutics and clinical risk management.
[60] H. Farkas,et al. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency , 2011, Expert review of clinical immunology.
[61] M. López-Trascasa,et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. , 2011, Journal of investigational allergology & clinical immunology.
[62] J. Nuijens,et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.
[63] B. Zuraw. The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.
[64] P. Keith,et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[65] J. Bernstein,et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.
[66] T. Klingebiel,et al. C1‐inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis , 2009, Transfusion.
[67] William H. Yang,et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[68] H. Farkas,et al. Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.
[69] K. Bork,et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.
[70] A. Eerenberg,et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.
[71] A. Tordai,et al. HAEdb: A novel interactive, locus‐specific mutation database for the C1 inhibitor gene , 2005, Human mutation.
[72] G. Hodge,et al. Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF‐beta as an immunomodulatory component in plasma‐derived factor VIII concentrate , 1999, British journal of haematology.
[73] J. Karsh,et al. C1-esterase inhibitor transfusions in patients with hereditary angioedema. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[74] P. Mannucci,et al. Transmission of hepatitis G virus in patients with angioedema treated with steam‐heated plasma concentrates of C1 inhibitor , 1998, Transfusion.
[75] P. Mannucci,et al. Reduction in transmission of hepatitis C after the introduction of a heat‐treatment step in the production of C1‐inhibitor concentrate , 1995, Transfusion.
[76] E. Hack,et al. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. , 1990, The Journal of clinical investigation.
[77] R. R. Evans,et al. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.